Aadi Bioscience Inc
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa… Read more
Aadi Bioscience Inc (AADI) - Net Assets
Latest net assets as of December 2024: $52.48 Million USD
Based on the latest financial reports, Aadi Bioscience Inc (AADI) has net assets worth $52.48 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($70.32 Million) and total liabilities ($17.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.48 Million |
| % of Total Assets | 74.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | 1234.41% |
| Growth Volatility | 180.4 |
Aadi Bioscience Inc - Net Assets Trend (2009–2024)
This chart illustrates how Aadi Bioscience Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aadi Bioscience Inc (2009–2024)
The table below shows the annual net assets of Aadi Bioscience Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $52.48 Million | -50.11% |
| 2023-12-31 | $105.19 Million | -33.58% |
| 2022-12-31 | $158.38 Million | +16.11% |
| 2021-12-31 | $136.41 Million | +1197.22% |
| 2020-12-31 | $-12.43 Million | -134.03% |
| 2019-12-31 | $36.54 Million | -37.72% |
| 2018-12-31 | $58.67 Million | +236.48% |
| 2017-12-31 | $17.44 Million | +239.92% |
| 2016-12-31 | $-12.46 Million | -416.85% |
| 2015-12-31 | $3.93 Million | +2636.53% |
| 2014-12-31 | $-155.04K | -24.79% |
| 2013-12-31 | $-124.24K | -30.04% |
| 2012-12-31 | $-95.54K | -40.14% |
| 2011-12-31 | $-68.18K | -66.32% |
| 2010-12-31 | $-40.99K | -120.43% |
| 2009-12-31 | $-18.60K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aadi Bioscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33260540000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $16.00K | 0.03% |
| Other Components | $385.11 Million | 733.86% |
| Total Equity | $52.48 Million | 100.00% |
Aadi Bioscience Inc Competitors by Market Cap
The table below lists competitors of Aadi Bioscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KMH Hitech Co. Ltd
KQ:052900
|
$17.04 Million |
|
Mustang Industrial
TWO:5460
|
$17.04 Million |
|
Chang Ho Fibre Corp
TW:1468
|
$17.05 Million |
|
Zhong An Group Limited
F:35Z
|
$17.05 Million |
|
Duro Felguera
MC:MDF
|
$17.03 Million |
|
ODTech Co. Ltd
KQ:080520
|
$17.03 Million |
|
First Ship Lease Trust
PINK:FSLUF
|
$17.02 Million |
|
Favelle Favco Bhd
KLSE:7229
|
$17.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aadi Bioscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 105,195,000 to 52,478,000, a change of -52,717,000 (-50.1%).
- Net loss of 63,691,000 reduced equity.
- Other comprehensive income decreased equity by 11,000.
- Other factors increased equity by 10,985,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.69 Million | -121.37% |
| Other Comprehensive Income | $-11.00K | -0.02% |
| Other Changes | $10.98 Million | +20.93% |
| Total Change | $- | -50.11% |
Book Value vs Market Value Analysis
This analysis compares Aadi Bioscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7321.43x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.00 | $2.05 | x |
| 2009-12-31 | $0.00 | $2.05 | x |
| 2010-12-31 | $-0.01 | $2.05 | x |
| 2011-12-31 | $-0.04 | $2.05 | x |
| 2012-12-31 | $-0.05 | $2.05 | x |
| 2013-12-31 | $-0.07 | $2.05 | x |
| 2014-12-31 | $-0.09 | $2.05 | x |
| 2015-12-31 | $2.18 | $2.05 | x |
| 2016-12-31 | $-6.91 | $2.05 | x |
| 2017-12-31 | $12.07 | $2.05 | x |
| 2018-12-31 | $25.94 | $2.05 | x |
| 2019-12-31 | $13.50 | $2.05 | x |
| 2020-12-31 | $-4.89 | $2.05 | x |
| 2021-12-31 | $15.29 | $2.05 | x |
| 2022-12-31 | $7.04 | $2.05 | x |
| 2023-12-31 | $3.91 | $2.05 | x |
| 2024-12-31 | $1.94 | $2.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aadi Bioscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -121.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -245.13%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.34x
- Recent ROE (-121.37%) is above the historical average (-181.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -2401.64% | 0.00% | 0.00x | 5.36x | $-33.76K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.30K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.58K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.63K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.94K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.20K |
| 2015 | -0.80% | 0.00% | 0.00x | 1.55x | $-424.71K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $1.21 Million |
| 2017 | -122.74% | 0.00% | 0.00x | 1.21x | $-23.14 Million |
| 2018 | -17.72% | -51.58% | 0.31x | 1.09x | $-16.26 Million |
| 2019 | -63.69% | -3106.88% | 0.02x | 1.09x | $-26.92 Million |
| 2020 | 0.00% | -24.84% | 0.74x | 0.00x | $-2.23 Million |
| 2021 | -80.71% | -11009.00% | 0.01x | 1.16x | $-123.73 Million |
| 2022 | -36.00% | -374.67% | 0.08x | 1.16x | $-72.85 Million |
| 2023 | -62.52% | -270.04% | 0.18x | 1.26x | $-76.28 Million |
| 2024 | -121.37% | -245.13% | 0.37x | 1.34x | $-68.94 Million |
Industry Comparison
This section compares Aadi Bioscience Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $65,661,514
- Average return on equity (ROE) among peers: -379.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aadi Bioscience Inc (AADI) | $52.48 Million | -2401.64% | 0.34x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |